BACKGROUND AND AIM: tumor necrosis factor (TNF)-α plays a significant role in the pathogenesis of nonalcoholic steatohepatitis (NASH). A few studies have confirmed high TNF-α plasma protein levels in patients with NASH compared to healthy volunteers. We herein aimed to revisit these findings using other molecular techniques. METHODS: a cross-sectional evaluation of patients newly diagnosed with NASH. A quantitative assay for the measurement of TNF-α messenger ribonucleic acid (mRNA) was performed for NASH patients and controls using real-time reverse transcription polymerase chain reaction (RT-PCR). RESULTS: in 39 patients with NASH (mean age 38.6 ± 9.4 years, range 28-60 years; 79% males), the mean TNF-α mRNA level was significantly higher than that found for controls (137.6 ± 102.3 ng/mL versus 83.5 ± 43.8 ng/mL, respectively; P = 0.012). A TNF-α mRNA cut-off of 100 ng/mL predicted NASH most optimally (AUC 0.685 ± 0.066, P = 0.01; with 66.7% sensitivity and 74.1% specificity). Serum TNF-α and soluble TNF-α receptor II (sTNFRII) levels were significantly higher in patients compared to controls using ELISA. CONCLUSION: high TNF-α mRNA levels, determined by RT-PCR, characterize patients with NASH.
BACKGROUND AND AIM: tumor necrosis factor (TNF)-α plays a significant role in the pathogenesis of nonalcoholic steatohepatitis (NASH). A few studies have confirmed high TNF-α plasma protein levels in patients with NASH compared to healthy volunteers. We herein aimed to revisit these findings using other molecular techniques. METHODS: a cross-sectional evaluation of patients newly diagnosed with NASH. A quantitative assay for the measurement of TNF-α messenger ribonucleic acid (mRNA) was performed for NASH patients and controls using real-time reverse transcription polymerase chain reaction (RT-PCR). RESULTS: in 39 patients with NASH (mean age 38.6 ± 9.4 years, range 28-60 years; 79% males), the mean TNF-α mRNA level was significantly higher than that found for controls (137.6 ± 102.3 ng/mL versus 83.5 ± 43.8 ng/mL, respectively; P = 0.012). A TNF-α mRNA cut-off of 100 ng/mL predicted NASH most optimally (AUC 0.685 ± 0.066, P = 0.01; with 66.7% sensitivity and 74.1% specificity). Serum TNF-α and soluble TNF-α receptor II (sTNFRII) levels were significantly higher in patients compared to controls using ELISA. CONCLUSION: high TNF-α mRNA levels, determined by RT-PCR, characterize patients with NASH.
Authors: Andrea Sonaglioni; Federica Cerini; Antonio Cerrone; Lorenzo Argiento; Gian Luigi Nicolosi; Elisabetta Rigamonti; Michele Lombardo; Maria Grazia Rumi; Mauro Viganò Journal: Intern Emerg Med Date: 2022-03-17 Impact factor: 5.472
Authors: Mark J Canet; Rhiannon N Hardwick; April D Lake; Anika L Dzierlenga; John D Clarke; Michael J Goedken; Nathan J Cherrington Journal: Drug Metab Dispos Date: 2014-12-08 Impact factor: 3.922
Authors: Tomas Laho; John D Clarke; Anika L Dzierlenga; Hui Li; David M Klein; Michael Goedken; Stanislav Micuda; Nathan J Cherrington Journal: Biochem Pharmacol Date: 2016-07-02 Impact factor: 5.858
Authors: Jay Luther; John J Garber; Hamed Khalili; Maneesh Dave; Shyam Sundhar Bale; Rohit Jindal; Daniel L Motola; Sanjana Luther; Stefan Bohr; Soung Won Jeoung; Vikram Deshpande; Gurminder Singh; Jerrold R Turner; Martin L Yarmush; Raymond T Chung; Suraj J Patel Journal: Cell Mol Gastroenterol Hepatol Date: 2015-03